VAKSIN MP; PERKEMBANGAN DAN

RENCANA IMPLEMENTASI
disampaikan oleh
Ni Nyoman Tri Puspaningsih
Universitas Airlangga
• PENDAHULUAN

• VAKSIN MERAH PUTIH

• VAKSIN VS VARIANT SARS-COV2

• REKOMENDASI
 PENDAHULUAN

University-CoE-BioME, Universitas Airlangga

University-CoE-BioME, Universitas Airlangga
In database {global} SARS-CoV-2 Genome

{As per 23 Juli 2021}

UCoE-BioME, Universitas Airlangga

In database {Indonesia} SARS-CoV-2 Genome

{As per 23 Juli 2021}

UCoE-BioME, Universitas Airlangga

MUTASI
Base pairs observed in Sars-Cov2 Genome

(Koyama,T. et al, Bulletin of the WHO, Juli 2020)

UCoE-BioME, Universitas Airlangga

Subject to mutations – major variants SARS-CoV-2 Genome

{Koyama et al., Bull World Health Organ 2020;98:495–504}

Indonesia/Surabaya: D614G / Q677H mutation in the Spike

UCoE-BioME, Universitas Airlangga

 DESAIN VAKSIN SARS-COV-2

TARGET
ANTIGEN

(Stephen N. C rooke, et al., Scientific Report, 2020)

{Naqvi, et. al., BBA - Molecular Basis of Disease 1866 (2020) 165878}
RBD binds the receptor human ACE2 SARS-CoV-2 Spike

{Lan et al., Nature, 581, 215-220 (2020)}

UCoE-BioME, Universitas Airlangga

For viral infection to occur … SARS-CoV-2

 S-protein is proteolytically  Upon viral entry to the host,

processed by host proteases the S2 domain is further
to generate non-covalently cleaved by a protease at S2'
bound S1 and S2.
{Villoutreix, B.O., IJMS, February 2021}

UCoE-BioME, Universitas Airlangga

VAKSIN MERAH PUTIH
Tim Vaksin Merah Putih - Universitas Airlangga
Vaccine Platform

(Debby van Riel et al., Nature Materials, August,2020)

 VAKSIN MERAH PUTIH
PT/LITBANG PLATFORM VAKSIN WAKTU
SEED VACCINE-
EUA/MASS
PRODUCTION
UNAIR 1. INACTIVATED VIRUS Feb.21 – Mar.’22
2. ADENOVIRUS Sept.21 -
3. PEPTIDA -
LEMBAGA BIOLOGI PROTEIN REKOMBINAN MAMALIA BASED - Sept. 22
MOLEKULAR EIJKMAN DAN YEAST BASED
LIPI PROTEIN REKOMBINAN FUSI SPIKE HEXA Agst.21 – Jun 23
PRO-FOLDON DAN RBD-FOLDON
ITB 1. ADENOVIRUS Sept.21 -
2. PROTEIN REKOMBINAN Sept.21 -
UGM PROTEIN REKOMBINAN KUARTAL 1 – 2022 -
UNPAD 1. PROTEIN REKOMBINAN Sept.21 – Sept.22
2. PEPTIDA
UI 1. DNA Okt.21 – Jul.22
2. mRNA Jan/Feb.22. -
3. Virus like particle Jun.22. -
 Rakernas Kemenristek/BRIN, Strategi Penguatan Vaksin
22/02/21
Merah Putih, Jogyakarta, 26-27 November 2020
 Grand Design Vaksin Merah-Putih Platform Inactive Unair-Biotis

100L/500L

PT.BIOTIS BPOM
Uji Preklinik pada GMP 20L
Vaksin hewan mice Pilot scala produksi
vaksin Uji Klinik Fase 2, (300)
Merah- transgenic
Putih 09 April-26 Mei 2021 15 Juni – 17 Juli 2021 1 Sept- 27 Nop 2021 Prod
Batch1
1 Maret 2022
UA BTS BTS BTS BTS BTS BTS BTS
BTS Eskalasi Produksi

12 Mei 2020-28 Feb 27 Mei - 10 Juli 2021 3 Agustus – 29 Okt 1 Nop-1 Feb 2022 Maret 2022
2021 Uji Preklinik pada 2021, Uji klinik Fase 1, Uji Klinik Fase 3, Produksi skala masal
Seed Virus hewan Maccaca (100) (3000) 300L/1500
Vaksin inaktif L
Platform Unair PSP-IPB
Multicente
r
RSUA

Catatan:
UA: Universitas Airlangga
BTS: Biotis

BPOM
EUA

Genomic Surveilance
Desain Vaksin berbasis Adenovirus Platform Viral Vector
Prinsip : Rekombinasi

(Agilent Tech. 2007)

VALIDASI HASIL KONSTRUKSI
pAd-RBD
RBD CCGATAGCTTCGTGATCAGGGGCGACGAGGTGCGCCAGATCGCTCCAGGACAGACCGGCA 386
R4T7 CCGATAGCTTCGTGATCAGGGGCGACGAGGTGCGCCAGATCGCTCCAGGACAGACCGGCA 480
************************************************************

RBD ----------------------------------GAATTCTGGTACCGACACCATGCCCA 26
RBD AGATCGCTGACTACAATTACAAGCTGCCCGACGATTTCACCGGCTGCGTGATCGCCTGGA 446
R4T7 CAATTCTCTAAGGAAATACTTAACCATGGTCGACTGGATCCGGTACCGACACCATGCCCA 120
R4T7 AGATCGCTGACTACAATTACAAGCTGCCCGACGATTTCACCGGCTGCGTGATCGCCTGGA 540
** ******************* ************************************************************

RBD TGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGATGCTGGTCGCTTCCGTCC 86
RBD ACTCCAACAATCTGGATAGCAAAGTGGGCGGCAACTACAATTACCTGTACCGCCTGTTCC 506
R4T7 TGGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTGGGGATGCTGGTCGCTTCCGTCC 180
R4T7 ACTCCAACAATCTGGATAGCAAAGTGGGCGGCAACTACAATTACCTGTACCGCCTGTTCC 600
************************************************************ ************************************************************
CD5
RBD TCGCTcgcgtgcagccaaccgagagcatcgtgcgcttccccAATATCACCAACCTGTGCC 146
RBD GCAAGTCCAATCTGAAGCCATTCGAGCGCGACATCTCCACCGAGATCTACCAGGCTGGAA 566
R4T7 TCGCTCGCGTGCAGCCAACCGAGAGCATCGTGCGCTTCCCCAATATCACCAACCTGTGCC 240
R4T7 GCAAGTCCAATCTGAAGCCATTCGAGCGCGACATCTCCACCGAGATCTACCAGGCTGGAA 660
************************************************************ ************************************************************
RBD
RBD CATTCGGCGAGGTGTTCAACGCTACCAGGTTCGCCAGCGTGTACGCTTGGAATCGCAAGC 206
RBD GCACCCCATGCAATGGAGTGGAGGGCTTCAACTGCTACTTCCCCCTGCAGAGCTACGGCT 626
R4T7 CATTCGGCGAGGTGTTCAACGCTACCAGGTTCGCCAGCGTGTACGCTTGGAATCGCAAGC 300
R4T7 GCACCCCATGCAATGGAGTGGAGGGCTTCAACTGCTACTTCCCCCTGCAGAGCTACGGCT 720
************************************************************ ************************************************************
RBD GCATCTCCAACTGCGTGGCCGACTACAGCGTGCTGTACAACTCCGCCAGCTTCTCCACCT 266
RBD TCCAGCCAACCAACGGAGTGGGATACCAGCCATACAGGGTGGTGGTGCTGTCCTTCGAGC 686
R4T7 GCATCTCCAACTGCGTGGCCGACTACAGCGTGCTGTACAACTCCGCCAGCTTCTCCACCT 360
R4T7 TCCAGCCAACCAACGGAGTGGGATACCAGCCATACAGGGTGGTGGTGCTGTCCTTCGAGC 780
************************************************************ ************************************************************
RBD TCAAGTGCTACGGCGTGTCCCCCACCAAGCTGAATGATCTGTGCTTCACCAACGTGTACG 326
RBD TGCTGCACGCTCCAGCTACCGTGTGCGGACCAAAGAAGAGCACCAATCTGGTGAAGAACA 746
R4T7 TCAAGTGCTACGGCGTGTCCCCCACCAAGCTGAATGATCTGTGCTTCACCAACGTGTACG 420
R4T7 TGCTGCACGCTCCAGCTACCGTGTGCGGACCAAAGAAGAGCACCAATCTGGTGAAGAACA 840
************************************************************ ************************************************************

RBD AGTGCGTGAACTTCAATTTCAACGGCCTGACCGGAACCGGCGTGCTGACCGAGTAGGTCG 806

R4T7 AGTGCGTGAACTTCAATTTCAACGGCCTGACCGGAACCGGCGTGCTGACCGAGTAGGTCG 900
************************************************************
Stop Kodon
RBD ACACTCGAGTGCGGCCGCA----------------------------------------- 825
R4T7 ACACTCGAGATATCTAGAACCCAGCTTTCTTGTACAAAGTGGTTGATCTAGAGGGCCCGC 960
********* * *

University-CoE-BioME, Universitas Airlangga

VALIDASI HASIL KONSTRUKSI
pAd-SWT
Spike461-1750 CACAAGAACAATAAGTCCTGGATGGAGAGCGAGTTCCGCGTGTACAGCTCCGCCAACAAT 120
pAdS6-sp468 CACAAGAACAATAAGTCCTGGATGGAGAGCGAGTTCCGCGTGTACAGCTCCGCCAACAAT 86
************************************************************

Spike461-1750 TGCACCTTCGAGTACGTGTCCCAGCCCTTCCTGATGGACCTGGAGGGCAAGCAGGGCAAT 180

pAdS6-sp468 TGCACCTTCGAGTACGTGTCCCAGCCCTTCCTGATGGACCTGGAGGGCAAGCAGGGCAAT 146
************************************************************

Spike -----------------GAATTCTGGTACCGACACCATGGATGCAATGAAGAGAGGGCTC 43 Spike461-1750 TTCAAGAACCTGCGCGAGTTCGTGTTCAAGAATATCGATGGCTACTTCAAGATCTACTCC 240

pAdS6-sp600Rev ACTTAACCATGGTCGACTGGATCCGGTACCGACACCATGGATGCAATGAAGAGAGGGCTC 540 pAdS6-sp468 TTCAAGAACCTGCGCGAGTTCGTGTTCAAGAATATCGATGGCTACTTCAAGATCTACTCC 206
** ************************************ ************************************************************

Spike TGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTCGCCCAGCTTTGTCTTCCTGGTC 103 Spike461-1750 AAGCACACCCCCATCAACCTGGTGCGCGACCTGCCACAGGGCTTCAGCGCCCTGGAGCCA 300

pAdS6-sp600Rev TGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTCGCCCAGCTTTGTCTTCCTGGTC 600 pAdS6-sp468 AAGCACACCCCCATCAACCTGGTGCGCGACCTGCCACAGGGCTTCAGCGCCCTGGAGCCA 266
************************************************************ ************************************************************
tPA Spike
Spike CTGCTGCCTCTGGTCTCGTCTCAGTGCGTGAACCTGACTACTAGAACCCAGCTGCCTCCT 163 Spike461-1750 CTGGTGGATCTGCCAATCGGCATCAACATCACCAGGTTCCAGACCCTGCTGGCCCTGCAC 360
pAdS6-sp600Rev CTGCTGCCTCTGGTCTCGTCTCAGTGCGTGAACCTGACTACTAGAACCCAGCTGCCTCCT 660 pAdS6-sp468 CTGGTGGATCTGCCAATCGGCATCAACATCACCAGGTTCCAGACCCTGCTGGCCCTGCAC 326
************************************************************ ************************************************************

Spike GCCTATACTAACTCCTTCACCCGCGGCGTGTACTACCCAGACAAGGTGTTCCGCAGCTCC 223 Spike461-1750 CGCAGCTACCTGACCCCAGGCGACAGCTCCAGCGGATGGACCGCTGGAGCTGCTGCCTAC 420

pAdS6-sp600Rev GCCTATACTAACTCCTTCACCCGCGGCGTGTACTACCCAGACAAGGTGTTCCGCAGCTCC 720 pAdS6-sp468 CGCAGCTACCTGACCCCAGGCGACAGCTCCAGCGGATGGACCGCTGGAGCTGCTGCCTAC 386
************************************************************ ************************************************************

Spike GTGCTGCACTCCACCCAGGATCTGTTCCTGCCCTTCTTCAGCAACGTGACCTGGTTCCAC 283 Spike461-1750 TACGTGGGCTACCTGCAGCCCCGCACCTTCCTGCTGAAGTACAACGAGAATGGCACCATC 480

pAdS6-sp600Rev GTGCTGCACTCCACCCAGGATCTGTTCCTGCCCTTCTTCAGCAACGTGACCTGGTTCCAC 780 pAdS6-sp468 TACGTGGGCTACCTGCAGCCCCGCACCTTCCTGCTGAAGTACAACGAGAATGGCACCATC 446
************************************************************ ************************************************************

Spike GCCATCCACGTGAGCGGCACCAATGGCACCAAGCGGTTCGACAATCCCGTGCTGCCATTC 343 Spike461-1750 ACCGACGCCGTGGATTGCGCCCTGGATCCACTGTCCGAGACAAAGTGCACCCTGAAGAGC 540

pAdS6-sp600Rev GCCATCCACGTGAGCGGCACCAATGGCACCAAGCGGTTCGACAATCCCGTGCTGCCATTC 840 pAdS6-sp468 ACCGACGCCGTGGATTGCGCCCTGGATCCACTGTCCGAGACAAAGTGCACCCTGAAGAGC 506
************************************************************ ************************************************************

Spike AACGATGGCGTGTACTTCGCCTCCACCGAGAAGAGCAACATCATCCGCGGCTGGATCTTC 403 Spike461-1750 TTCACCGTGGAGAAGGGCATCTACCAGACCTCCAATTTCCGCGTGCAGCCAACCGAGAGC 600

pAdS6-sp600Rev AACGATGGCGTGTACTTCGCCTCCACCGAGAAGAGCAACATCATCCGCGGCTGGATCTTC 900 pAdS6-sp468 TTCACCGTGGAGAAGGGCATCTACCAGACCTCCAATTTCCGCGTGCAGCCAACCGAGAGC 566
************************************************************ ************************************************************

Spike GGCACCACCCTGGACTCCAAGACCCAGAGCCTGCTGATCGTGAACAATGCCACCAACGTG 463 Spike461-1750 ATCGTGCGCTTCCCCAATATCACCAACCTGTGCCCATTCGGCGAGGTGTTCAACGCTACC 660

pAdS6-sp600Rev GGCACCACCCTGGACTCCAAGACCCAGAGCCTGCTGATCGTGAACAATGCCACCAACGTG 960 pAdS6-sp468 ATCGTGCGCTTCCCCAATATCACCAACCTGTGCCCATTCGGCGAGGTGTTCAACGCTACC 626
************************************************************ ************************************************************

Spike GTCATCAAGGTGTGCGAGTTCCAGTTCTGCAATGATCCATTCCTGGGCGTGTACTACCAC 523 Spike461-1750 AGGTTCGCCAGCGTGTACGCTTGGAATCGCAAGCGCATCTCCAACTGCGTGGCCGACTAC 720

pAdS6-sp600Rev GTCATCAAGGTGTGCGAGTTCCAGTTCTGCAATGATCCATTCCTGGGCGTGTACTACCAC 1020 pAdS6-sp468 AGGTTCGCCAGCGTGTACGCTTGGAATCGCAAGCGCATCTCCAACTGCGTGGCCGACTAC 686
************************************************************ ************************************************************

University-CoE-BioME, Universitas Airlangga

 VALIDASI HASIL KONSTRUKSI
pAd-SMt
SMut468-1800 ACAACAAGAGCTGGATGGAATCTGAATTCAGAGTGTACAGCAGCGCCAACAATTGTACAT 120
pAdSMut4-SMP468 ACAACAAGAGCTGGATGGAATCTGAATTCAGAGTGTACAGCAGCGCCAACAATTGTACAT 89
************************************************************

Spike ---------------------------------------GAATTCTGGTACCGACACCAT 21 SMut468-1800 TTGAGTACGTGAGCCAACCGTTTCTGATGGACCTTGAAGGCAAGCAGGGCAACTTCAAAA 180

pAdSMutS4-sp600Rev AGAACCAATTCTCTAAGGAAATACTTAACCATGGTCGACTGGATCCGGTACCGACACCAT 660 pAdSMut4-SMP468 TTGAGTACGTGAGCCAACCGTTTCTGATGGACCTTGAAGGCAAGCAGGGCAACTTCAAAA 149
** ************** ************************************************************

Spike GGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTC 81 SMut468-1800 ACCTTAGAGAGTTCGTGTTCAAGAACATCGACGGATATTTCAAGATCTACAGCAAGCACA 240

pAdSMutS4-sp600Rev GGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTTTC 720 pAdSMut4-SMP468 ACCTTAGAGAGTTCGTGTTCAAGAACATCGACGGATATTTCAAGATCTACAGCAAGCACA 209
************************************************************ ************************************************************
tPA SMut468-1800 CCCCTATTAACCTGGTTCGGGACCTGCCTCAGGGATTTAGCGCCCTGGAGCCCCTGGTCG 300
Spike GCCCAGCTTCGTGTTCCTCGTGTTACTGCCACTGGTGTCCTCCCAGTGCGTGAACCTGAC 141
pAdSMutS4-sp600Rev GCCCAGCTTCGTGTTCCTCGTGTTACTGCCACTGGTGTCCTCCCAGTGCGTGAACCTGAC 780 pAdSMut4-SMP468 CCCCTATTAACCTGGTTCGGGACCTGCCTCAGGGATTTAGCGCCCTGGAGCCCCTGGTCG 269
************************************************************ ************************************************************
Spike Mutan
Spike CACCCGGACACAGCTGCCTCCTGCCTACACCAACTCCTTCACCCGGGGAGTCTACTACCC 201 SMut468-1800 ACCTGCCTATCGGCATCAACATCACCAGATTCCAGACCCTGCTTGCTCTGCACAGATCCT 360
pAdSMutS4-sp600Rev CACCCGGACACAGCTGCCTCCTGCCTACACCAACTCCTTCACCCGGGGAGTCTACTACCC 840 pAdSMut4-SMP468 ACCTGCCTATCGGCATCAACATCACCAGATTCCAGACCCTGCTTGCTCTGCACAGATCCT 329
************************************************************ ************************************************************

Spike TGATAAGGTGTTCAGGAGCAGCGTGCTGCATTCTACACAGGATCTTTTCCTGCCTTTCTT 261 SMut468-1800 ACCTGACCCCTGGCGACAGCAGCAGCGGCTGGACCGCCGGAGCCGCTGCCTACTATGTAG 420

pAdSMutS4-sp600Rev TGATAAGGTGTTCAGGAGCAGCGTGCTGCATTCTACACAGGATCTTTTCCTGCCTTTCTT 900 pAdSMut4-SMP468 ACCTGACCCCTGGCGACAGCAGCAGCGGCTGGACCGCCGGAGCCGCTGCCTACTATGTAG 389
************************************************************ ************************************************************

Spike CTCCAACGTCACATGGTTCCACGCCATTCACGTGTCTGGCACCAACGGCACCAAGCGGTT 321 SMut468-1800 GCTACCTGCAGCCTAGAACCTTTCTGCTGAAATACAACGAGAACGGCACCATCACCGACG 480

pAdSMutS4-sp600Rev CTCCAACGTCACATGGTTCCACGCCATTCACGTGTCTGGCACCAACGGCACCAAGCGGTT 960 pAdSMut4-SMP468 GCTACCTGCAGCCTAGAACCTTTCTGCTGAAATACAACGAGAACGGCACCATCACCGACG 449
************************************************************ ************************************************************

Spike TGATAACCCCGTGCTGCCTTTCAACGACGGCGTCTACTTCGCCTCTACAGAGAAGAGCAA 381 SMut468-1800 CCGTAGACTGTGCGCTGGATCCCCTGAGCGAGACAAAGTGCACCCTGAAGTCTTTTACTG 540

pAdSMutS4-sp600Rev TGATAACCCCGTGCTGCCTTTCAACGACGGCGTCTACTTCGCCTCTACAGAGAAGAGCAA 1020 pAdSMut4-SMP468 CCGTAGACTGTGCGCTGGATCCCCTGAGCGAGACAAAGTGCACCCTGAAGTCTTTTACTG 509
************************************************************ ************************************************************

Spike CATCATCAGAGGCTGGATCTTCGGCACAACCCTGGACAGCAAGACCCAGTCCCTGCTGAT 441 SMut468-1800 TGGAAAAGGGGATCTATCAGACCTCCAATTTTAGAGTGCAGCCCACCGAATCTATTGTGC 600

pAdSMutS4-sp600Rev CATCATCAGAGGCTGGATCTTCGGCACAACCCTGGACAGCAAGACCCAGTCCCTGCTGAT 1080 pAdSMut4-SMP468 TGGAAAAGGGGATCTATCAGACCTCCAATTTTAGAGTGCAGCCCACCGAATCTATTGTGC 569
************************************************************ ************************************************************

Spike AGTGAACAATGCCACAAATGTGGTGATCAAAGTCTGCGAGTTCCAGTTCTGCAACGACCC 501 SMut468-1800 GGTTCCCTAACATTACCAATCTTTGTCCTTTTGGTGAGGTGTTCAACGCCACCAGATTCG 660

pAdSMutS4-sp600Rev AGTGAACAATGCCACAAATGTGGTGATCAAAGTCTGCGAGTTCCAGTTCTGCAACGACCC 1140 pAdSMut4-SMP468 GGTTCCCTAACATTACCAATCTTTGTCCTTTTGGTGAGGTGTTCAACGCCACCAGATTCG 629
************************************************************ ************************************************************

Spike TTTCCTGGGTGTGTACTACCATAAGAACAACAAGAGCTGGATGGAATCTGAATTCAGAGT 561 SMut468-1800 CCAGCGTTTACGCCTGGAATAGAAAGCGCATCTCTAACTGCGTTGCCGACTACAGCGTGC 720

pAdSMutS4-sp600Rev TTTCCTGGGTGTGTACTACCATAAGAACAACAAGAGCTGGATGGAATCTGAATTCAGAGG 1200 pAdSMut4-SMP468 CCAGCGTTTACGCCTGGAATAGAAAGCGCATCTCTAACTGCGTTGCCGACTACAGCGTGC 689
*********************************************************** ************************************************************

University-CoE-BioME, Universitas Airlangga

 KONSEP PENGEMBANGAN VAKSIN PEPTIDA

• Kandidat vaksin peptida UNAIR (PeptAIR) → usaha ilmiah untuk mengeksploitasi

prinsip imunologis dari infeksi COVID-19.
• Peptida epitop dari protein struktural virus SARS-CoV-2 mampu membentuk sel
memori atau pengingat yang akan melindungi donor dari penyakit COVID-19.

{TIM BIOMOL-FK, UNAIR, 2020}

 Prediksi B-cell Epitope pada Spike Sars-Cov-2

Stephen N. C rooke, et al., Scientific Report, 2020

 VAKSIN VS VARIANT
SARS-COV2

University-CoE-BioME, Universitas Airlangga

 Variants of concern (VOC) Mutation at Spike

(G/452R.V3 (B 1.617)
India
1.617.1 dan 1.617.3 : L452R, E484Q, P681R K417N T478K D614G P681R
1.617.2 : T478K, DELTA PLUS : K417N E484Q
L452R

[Ashley Hagen, M.S. is the Science Communications Specialist at the American Society for Microbiology. (March, 2021)]

UCoE-BioME, Universitas Airlangga

D614G mutation
worldwide (23 July 2021)
2.407.373 times; 97.96%;
193 countries)
Indonesia:
3296 times, 96.74%)

POINT
MUTATION
D614G
 Interaksi RBD_ACE2

{Villoutreix, B.O., IJMS, February 2021}

UCoE-BioME, Universitas Airlangga

The site is absent in other coronaviruses SARS-CoV-2 Spike

{Jaimes et al., iScience 23, 101212 (2020)}

BioME, Universitas Airlangga

It has a furin-like cleavage site SARS-CoV-2 Spike

{Coutard et al., Antiviral Res, 176, 104742 (2020)}

UCoE-BioME, Universitas Airlangga

It has a furin-like cleavage site SARS-CoV-2 Spike

677H 681H (Alpha)

(Sby-Ind) 681R (Delta) {Coutard et al., Antiviral Res, 176, 104742 (2020)}

UCoE-BioME, Universitas Airlangga

The site interacts with human furin SARS-CoV-2 Spike

Binding Energy (kkal/mol) GISAID DATA 23072021

Spike-WT -49.10
Spike-Mutant (Q677H) -58.17 35,308
Spike-Mutant (P681R) -52.62 263,582
Spike-Mutant (P681H) -62.17 1.098.017
{BIOME TEAM, UNAIR, 2020-2021,unpublished data}

BioME, Universitas Airlangga

(WHO, 8 JULI 2021)
 REKOMENDASI

UCoE-BioME, Universitas Airlangga

 1. Akselerasi Vaksinasi akan mempercepat
tercapainya Herd Immunity

2. Patuhi Protokol Kesehatan dengan sangat ketat

3. Strategi konstruksi dan desain vaksin terkait

point mutation esensial pada Virus Sars-Cov2

{Mutant Spike modelling by Biome team, UNAIR, 2020-

2021, unpublished data}

UCoE-BioME, Universitas Airlangga

(WHO, 8 July 2021)
 TERIMA KASIH

UCoE-BioME, Universitas Airlangga